DPP-IV inhibitors could be cost-effective for T2DM

Author：

ISSN： 1173-8324

Source： Inpharma, Vol.1, Iss.1642, 2008-01, pp. : 4-4

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

DPP-IV inhibitors could be cost-effective for T2DM

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 556, 2008-01 ,pp. : 5-5

Adis International

Access to resources Recommend Favorite

Computational Identification of Inhibitors Against DPP-IV for Checking Type-2 Diabetes

Letters in Drug Design & Discovery, Vol. 14, Iss. 1, 2017-01 ,pp. : 66-73

Bentham Science Publishers

Access to resources Recommend Favorite

11 Years of Cyanopyrrolidines as DPP-IV Inhibitors

Current Topics in Medicinal Chemistry, Vol. 7, Iss. 6, 2007-03 ,pp. : 579-595

Bentham Science Publishers

Access to resources Recommend Favorite

Sixteen-Years of Clinically Relevant Dipeptidyl Peptidase-IV (DPP-IV) Inhibitors for Treatment of Type-2 Diabetes: A Perspective

Current Medicinal Chemistry, Vol. 21, Iss. 35, 2014-01 ,pp. : 4013-4045

Bentham Science Publishers

Access to resources Recommend Favorite

Treatment of Type 2 diabetes mellitus with agonists of the GLP-1 receptor or DPP-IV inhibitors

By Holst Jens Juul

Expert Opinion on Emerging Drugs, Vol. 9, Iss. 1, 2004-05 ,pp. : 155-166

Informa Healthcare

Access to resources Recommend Favorite